Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-400
- Development stage
- Preclinical
- Lead developer
- Nectin Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
NTX-400 is a preclinical-stage monoclonal antibody developed by Nectin Therapeutics that targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is an inhibitory immune checkpoint receptor expressed on various immune cells, including T cells and Natural Killer (NK) cells. By binding to TIGIT, NTX-400 prevents its interaction with ligands such as CD155 (PVR), thereby relieving immune suppression and enhancing the body's anti-tumor immune response. The drug is currently being developed for the treatment of advanced solid tumors.
Beyond the preview
Go deeper on NTX-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-400.